Overview

Phase 2 Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With IPF

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.
Phase:
Phase 2
Details
Lead Sponsor:
Nerre Therapeutics Ltd.
Collaborator:
Pharm-Olam International
Treatments:
Maleic acid